<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03284879</url>
  </required_header>
  <id_info>
    <org_study_id>CC-10004-PSOR-018</org_study_id>
    <nct_id>NCT03284879</nct_id>
  </id_info>
  <brief_title>Post-Marketing Surveillance Study of OTEZLA</brief_title>
  <official_title>OTEZLAÂ® Tablets Drug Use-Results Survey</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celgene</source>
  <brief_summary>
    <textblock>
      To evaluate the safety and efficacy of OTEZLA in actual clinical settings of use in patients
      with Psoriasis vulgaris that is with an inadequate response to topical therapies and
      Psoriasis arthropathica

        1. Planned registration period 2 years

        2. Planned surveillance period for 4 years from 6 months after launch
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 5, 2017</start_date>
  <completion_date type="Anticipated">August 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events (AEs)</measure>
    <time_frame>Up to approximately 12 months</time_frame>
    <description>Number of participants with adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>General Improvement Rating</measure>
    <time_frame>Approximately 1 year from administration</time_frame>
    <description>General Improvement Rating will be assessed by physician's observation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>General health assessment on VAS</measure>
    <time_frame>Approximately 1 year from administration</time_frame>
    <description>Visual Analog Scale (VAS) pain will be used for psoriatic arthritis patients' assessment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in physician general assessment</measure>
    <time_frame>Approximately 1 year from administration</time_frame>
    <description>PGA: assessment for psoriatic vulgaris by physician to classify disease activity in a consistent manner</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of patients with Dermatology Life Quality Index (DLQI)</measure>
    <time_frame>Approximately 1 year from administration</time_frame>
    <description>The Dermatology Life Quality Index or DLQI is a dermatology-specific Quality of Life instrument. It is a simple 10-question validated questionnaire</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline activity for arthritis</measure>
    <time_frame>Approximately 1 year from administration</time_frame>
    <description>Activity for arthritis Baseline is calculated by Disease Activity Score-DAS28 method</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Patients with PsV and PsA treated with OTEZLA Tablets</arm_group_label>
    <description>Patients with psoriasis vulgaris and patients with psoriatic arthritis who are treated with OTEZLA Tablets</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who have received a diagnosis of either of the following diseases and have
        received OTEZLA for the first time will be included in this survey.

          -  Psoriasis vulgaris that is with an inadequate response to topical therapies

          -  Psoriasis arthropathica
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Patients who have received a diagnosis of either of the following diseases and have
        received OTEZLA for the first time will be included in this survey.

          -  Psoriasis vulgaris that is with an inadequate response to topical therapies

          -  Psoriasis arthropathica

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyoko Matsui</last_name>
    <role>Study Director</role>
    <affiliation>Celgene</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shigeru Minohara, Study manager</last_name>
    <phone>+81-3-5224-0660</phone>
    <email>sminohara@celgene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tugi dermatology clinic</name>
      <address>
        <city>Kitakyushu</city>
        <state>Fukuoka</state>
        <zip>804-0081</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 31, 2017</study_first_submitted>
  <study_first_submitted_qc>September 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 15, 2017</study_first_posted>
  <last_update_submitted>September 13, 2017</last_update_submitted>
  <last_update_submitted_qc>September 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Psoriasis vulgaris</keyword>
  <keyword>Psoriasis arthropathica</keyword>
  <keyword>Serious infections</keyword>
  <keyword>Gastrointestinal Disorders</keyword>
  <keyword>Serious Hypersensitivity</keyword>
  <keyword>Weight Decrease</keyword>
  <keyword>Vasculitis</keyword>
  <keyword>Malignancies</keyword>
  <keyword>Depression and Suicidal Ideation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apremilast</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

